A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types

Summary

The aim of this study is to retrospectively collect clinical information on patients with extranodal or rare lymphomas, and to explore the best treatment strategy for these lymphomas in the real-world population.

Conditions

• Lymphoma
• Extranodal Lymphoma
• Diffuse Large B Cell Lymphoma
• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Marginal Zone Lymphoma
• Mucosa-Associated Lymphoid Tissue Lymphoma
• NK/T-Cell Lymphoma, Nasal and Nasal-Type
• Intravascular Large B-Cell Lymphoma

Interventions

OTHER

No interventions need to be specified for this study

No interventions need to be specified for this study

Sponsors & Collaborators

• Nanfang Hospital, Southern Medical University

  collaborator OTHER

• Fujian Medical University Union Hospital

  collaborator OTHER

• Peking University Third Hospital

  collaborator OTHER

• Peking University People's Hospital

  collaborator OTHER

• Peking Union Medical College Hospital

  collaborator OTHER

• Beijing Hospital

  collaborator OTHER_GOV

• The Second Affiliated Hospital of Dalian Medical University

  collaborator OTHER

• The First Affiliated Hospital of Guangzhou Medical University

  collaborator OTHER

• Henan Provincial People's Hospital

  collaborator OTHER

• Hunan Cancer Hospital

  collaborator OTHER

• Henan Cancer Hospital

  collaborator OTHER_GOV

• The First Hospital of Jilin University

  collaborator OTHER

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

  collaborator OTHER

• Affiliated Hospital of Nantong University

  collaborator OTHER

• The First Affiliated Hospital of Xiamen University

  collaborator OTHER

• Shandong Provincial Hospital

  collaborator OTHER_GOV

• Shanxi Province Cancer Hospital

  collaborator OTHER

• RenJi Hospital

  collaborator OTHER

• Beijing Friendship Hospital

  collaborator OTHER

• West China Hospital

  collaborator OTHER

• The First Affiliated Hospital of Soochow University

  collaborator OTHER

• Tongji Hospital

  collaborator OTHER

• Second Affiliated Hospital, School of Medicine, Zhejiang University

  collaborator OTHER

• Sun Yat-sen University

  collaborator OTHER

• Chongqing University Cancer Hospital

  collaborator OTHER

• Anhui Provincial Cancer Hospital

  collaborator OTHER

• The General Hospital of Northern Theater Command

  collaborator OTHER

• Qilu Hospital of Shandong University

  collaborator OTHER

• Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

  collaborator OTHER

• The Affiliated Hospital Of Guizhou Medical University

  collaborator OTHER

• Wuhan TongJi Hospital

  collaborator OTHER

• General Hospital of Ningxia Medical University

  collaborator OTHER

• The First Affiliated Hospital of Nanchang University

  collaborator OTHER

• The First Affiliated Hospital with Nanjing Medical University

  collaborator OTHER

• Anshan Central Hospital

  collaborator OTHER

• Hainan Cancer Hospital

  collaborator OTHER

• Fifth Affiliated Hospital of Guangzhou Medical University

  collaborator OTHER

• The First Affiliated Hospital of Anhui Medical University

  collaborator OTHER

• The Affiliated Hospital of Xuzhou Medical University

  collaborator OTHER

• First Affiliated Hospital of Harbin Medical University

  collaborator OTHER

• Zhujiang Hospital

  collaborator OTHER

• Ruijin Hospital

  lead OTHER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-07-01

Primary Completion

2024-03-01

Completion

2024-10-01

Countries

• China

Study Locations